Robert A. Heft
Director/Board Member at CLEMENTIA PHARMACEUTICALS INC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Hawkins | M | 75 |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | 14 years |
| Ed Mathers Mathers | M | 64 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | 11 years |
| Paul Baehr | M | - | 29 years | |
| Robert de Luccia | M | 78 | 24 years | |
| Brian Mueller | M | 50 | 22 years | |
| Murray Hinz | M | 55 |
Parvus Therapeutics, Inc.
 Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Parvus Therapeutics, Inc. manufactures and sells biopharmaceutical products. The private company is based in Calgary, Canada. | 7 years |
| Elaine Heron | M | 76 | 22 years | |
| Simon Read | M | 53 | 8 years | |
| Cameron Wheeler | M | 45 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| An van Es-Johansson | M | 64 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | 3 years |
| Ramin Farzaneh-Far | M | 47 | 8 years | |
| Peter DiRoma | M | - | 6 years | |
| Dhavalkumar Patel | M | 63 | 4 years | |
| Emmanuel Lacroix | M | - |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Abhinav Kumar | M | - | 4 years | |
| Ahmed Ghoniem | M | 72 |
Massachusetts Institute of Technology
| 41 years |
| Lazar Dimitrov | M | - |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Charles A. Johnson | M | 73 |
Parvus Therapeutics, Inc.
Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Parvus Therapeutics, Inc. manufactures and sells biopharmaceutical products. The private company is based in Calgary, Canada. | 5 years |
| Jeffrey Packman | M | 57 | 11 years | |
| Charl van Zyl | M | 57 | 4 years | |
| James M. Roach | M | 64 | - | |
| Richard Young | M | 70 |
Massachusetts Institute of Technology
| 40 years |
| Emmett Cunningham | M | 63 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Michael Cima | M | 64 |
Massachusetts Institute of Technology
| 38 years |
| Kevin Lalande | M | 51 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | - |
| Carole Nüchterlein | F | 62 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | 7 years |
| Hugh Young Rienhoff | M | 71 |
Parvus Therapeutics, Inc.
Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Parvus Therapeutics, Inc. manufactures and sells biopharmaceutical products. The private company is based in Calgary, Canada. | 5 years |
| J. David Litster | M | 85 |
Massachusetts Institute of Technology
| 41 years |
| Denelle Waynick | F | 57 | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Clarissa Desjardins | M | 57 | 8 years | |
| Javier de Luis | M | - |
Massachusetts Institute of Technology
| 10 years |
| Morris Kesler | M | - |
Massachusetts Institute of Technology
| 8 years |
| David Miller | M | - |
Massachusetts Institute of Technology
| 21 years |
| Silvia Noiman | M | 68 | 4 years | |
| Thomas Kurfess | M | - |
Massachusetts Institute of Technology
| 7 years |
| Yoo-Hwan Jang | M | 69 |
Massachusetts Institute of Technology
| 3 years |
| John S. Langford | M | - |
Massachusetts Institute of Technology
| 5 years |
| David Bonita | M | 48 | 6 years | |
| Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 11 years |
| Tomer Kariv | M | 62 | 6 years | |
| Anastasios Aslidis | M | 64 |
Massachusetts Institute of Technology
| 5 years |
| Walid Fakhry | M | - |
Massachusetts Institute of Technology
| 6 years |
| Ran Nussbaum | M | 51 | 5 years | |
| Jerry L. Prince | M | - |
Massachusetts Institute of Technology
| 6 years |
| Gregg Burgess | M | - |
Massachusetts Institute of Technology
| 5 years |
| Jocelyn E. Scott | F | - |
Massachusetts Institute of Technology
| 4 years |
| Timothy Pearson | M | 56 | 4 years | |
| Michael Singer | M | 60 | 3 years | |
| Brad Feld | M | 58 |
Massachusetts Institute of Technology
| 5 years |
| Barbara Poggiali | M | 61 |
Massachusetts Institute of Technology
| 5 years |
| Guo Zhong Xie | M | 64 |
Massachusetts Institute of Technology
| 4 years |
| Subodh Kulkarni | M | 60 |
Massachusetts Institute of Technology
| 4 years |
| Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 years |
| Gadi Veinrib | M | 45 | 5 years | |
| Mark Jennings | M | 63 |
Massachusetts Institute of Technology
| 5 years |
| Warren Chou | M | - |
Massachusetts Institute of Technology
| 6 years |
| Sung-Hwan Shin | M | 61 |
Massachusetts Institute of Technology
| 7 years |
| Brian Eric Thompson | M | - |
Massachusetts Institute of Technology
| 5 years |
| Kyu-Ha Cung | M | 72 |
Massachusetts Institute of Technology
| 7 years |
| Alexander Cumbo | M | 53 | 2 years | |
| Zafrira Avnur | M | 73 | 5 years | |
| Aoife Brennan | M | 48 | 2 years | |
| Steve Forte | M | 45 | 1 years | |
| Thomas H. Lee | M | 64 |
Massachusetts Institute of Technology
| 6 years |
| Jason Lettmann | M | 46 | 3 years | |
| Suresh Thirugnanam | M | 60 |
Massachusetts Institute of Technology
| 4 years |
| Louis C. Drapeau | M | 79 | 3 years | |
| Christopher J. Neil | M | 58 |
Massachusetts Institute of Technology
| 6 years |
| Francois Nader | M | 67 | 5 years | |
| David Mott | M | 58 | 3 years | |
| Raymond Anderson | M | 82 | 4 years | |
| Philippe Laffont | M | - |
Massachusetts Institute of Technology
| 6 years |
| Brian Jacobs | M | 63 |
Massachusetts Institute of Technology
| 5 years |
| Martijn Kleijwegt | M | 69 | 4 years | |
| Sameer Gandhi | M | 58 |
Massachusetts Institute of Technology
| 15 years |
| Joe Schirripa | M | - |
Massachusetts Institute of Technology
| 6 years |
| Anita Killian | F | - |
Massachusetts Institute of Technology
| 5 years |
| Mike McElroy | M | - |
Massachusetts Institute of Technology
| 9 years |
| Rubin Bahar | M | - |
Massachusetts Institute of Technology
| 4 years |
| King C. Lee | M | - | 3 years | |
| Jean-François Pariseau | M | 54 | 6 years | |
| Spiros Jamas | M | 63 |
Massachusetts Institute of Technology
| 5 years |
| John A. DeTore | M | - |
Massachusetts Institute of Technology
| 7 years |
| Joshua Grass | M | - | 14 years | |
| Ford Tamer | M | 62 |
Massachusetts Institute of Technology
| 5 years |
| Raj Shah | M | 46 | 5 years | |
| Robert E. Ward | M | 66 | 3 years | |
| David E. Culler | M | - |
Massachusetts Institute of Technology
| 5 years |
| Jon Hirschtick | M | - |
Massachusetts Institute of Technology
| 5 years |
| Ayman Mahmoud Hindy | M | - |
Massachusetts Institute of Technology
| 4 years |
| Peter Bisgaard | M | 50 | 4 years | |
| James F. Butler | M | - |
Massachusetts Institute of Technology
| 6 years |
| Ken Kharbanda | M | - |
Massachusetts Institute of Technology
| 3 years |
| Allan Mandelzys | M | 58 | 6 years | |
| Bert Richards | M | - |
Massachusetts Institute of Technology
| 5 years |
| Walid Fakhry | M | - |
Massachusetts Institute of Technology
| 6 years |
| Nathan Bryson | M | 61 |
Massachusetts Institute of Technology
| 3 years |
| Ramin Hojati | M | - |
Massachusetts Institute of Technology
| 4 years |
| Nancy L. Rose | M | 64 |
Massachusetts Institute of Technology
| 3 years |
| Natalie Lorenz-Anderson | F | 61 |
Massachusetts Institute of Technology
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 83 | 83.00% |
| Canada | 18 | 18.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert A. Heft
- Personal Network
